Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18073438 | 0.98 | KMT2A (0.31) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL13445910 | 0.96 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL13499235 | 0.95 | ALOX12 (0.33) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL127754 | 0.95 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL19698794 | 0.93 | ALOX12 (0.35) | SMN1; SMN2PSMB8ALOX12PSMB5HPGD | |
| SCHEMBL126659 | 0.93 | PSMB8 (0.33) | PSMB8ALOX12PSMB5 | |
| SCHEMBL18768872 | 0.92 | ALOX12 (0.34) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL18751743 | 0.92 | ALOX12 (0.34) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL18751742 | 0.92 | ALOX12 (0.34) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 | |
| SCHEMBL28711763 | 0.91 | ALOX12 (0.36) | SMN1; SMN2KMT2APSMB8ALOX12PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210128516-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | NOVARTIS AG (CH) | 2021-05-06 | — | — | US | disclosed |
| US-20200268741-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-10543207-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190070169-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LIMITED (GB) | 2019-03-07 | — | — | US | disclosed |
| US-9999657-B2 | Polymer-factor VIII moiety conjugates | NEKTAR THERAPEUTICS (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180071404-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-20170340623-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | SMN1; SMN2 3568/4885KMT2A 1613/4885PSMB8 979/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SMN1; SMN2 1435/4885KMT2A 1159/4885PSMB8 358/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | SMN1; SMN2 2381/4885KMT2A 2142/4885PSMB8 1334/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | SMN1; SMN2 1435/4885KMT2A 1159/4885PSMB8 358/4885 |
| US-20170340623-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | SMN1; SMN2 2765/4885KMT2A 3647/4885PSMB8 2291/4885 |
| US-20190070169-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | SMN1; SMN2 2317/4885KMT2A 2437/4885PSMB8 1805/4885 |
| US-20210128516-A1 | CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO | SDCBP, DDOST, CD47 | SMN1; SMN2 1957/4885KMT2A 4458/4885PSMB8 1426/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | SMN1; SMN2 2765/4885KMT2A 3647/4885PSMB8 2291/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | SMN1; SMN2 1544/4885KMT2A 1868/4885PSMB8 3115/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | SMN1; SMN2 3529/4885KMT2A 1218/4885PSMB8 1925/4885 |
| US-10543207-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | SMN1; SMN2 2765/4885KMT2A 3647/4885PSMB8 2291/4885 |
| US-20180071404-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | SMN1; SMN2 3422/4885KMT2A 1678/4885PSMB8 1967/4885 |
| US-20200268741-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | SMN1; SMN2 2765/4885KMT2A 3647/4885PSMB8 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.